Загрузка...
Copper chelation as targeted therapy in a mouse model of oncogenic BRAF-driven papillary thyroid cancer
PURPOSE: 60% of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation. Inhibitors of BRAF and its substrates MEK1/2 are showing clinical promise in BRAF(V600E) PTC. PTC progression can be decades long, which is challenging in terms of toxicity and cost. We previously found that MEK...
Сохранить в:
| Опубликовано в: : | Clin Cancer Res |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6125179/ https://ncbi.nlm.nih.gov/pubmed/30065097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3705 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|